8-K: BioLife Solutions Reports Strong Q3 2025, Raises Guidance

BioLife Solutions announced robust third-quarter 2025 financial results, driven by a 33% increase in Cell Processing revenue, and raised its full-year revenue guidance after divesting its evo cold chain logistics business.

Summary

• Total revenue for the third quarter of 2025 was $28.1 million, an increase of 31% from $21.4 million in Q3 2024.
• Cell Processing revenue reached $25.4 million, up 33% from the same period in 2024, primarily due to strong demand from commercial customers.
• GAAP gross margin for Q3 2025 was 62%, while non-GAAP adjusted gross margin was 64%.
• GAAP net income for Q3 2025 was $0.6 million, compared to a net loss of $0.5 million in Q3 2024.
• Non-GAAP adjusted EBITDA for Q3 2025 was $7.8 million, representing 28% of revenue, up from $5.0 million (23% of revenue) in Q3 2024.
• The company completed the sale of its evo cold chain logistics subsidiary on October 6, 2025, for $25.5 million in cash.
• Full-year 2025 Cell Processing revenue guidance was raised to $93.0 million $94.0 million, representing 26% to 28% year-over-year growth.
• Full-year 2025 total revenue guidance, adjusted for the evo sale, is $95.0 million $96.0 million, an increase of 27% 29% compared to 2024 continuing operations.
• Biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., holding over 70% market share, including nearly 80% of Phase III trials.
• Biopreservation media is embedded in 16 unique commercial cell and gene therapies (CGTs), with expectations for 10 additional approvals, expansions, or new indications over the next 12 months.

Sentiment

Score: 8

Explanation: The company delivered strong Q3 2025 results with significant revenue growth in its core business, improved profitability metrics (GAAP net income, adjusted EBITDA), and a strategic divestiture of a non-core asset. The raised full-year guidance further reinforces a very positive operational and strategic outlook.

Positives

• Delivered strong Cell Processing revenue growth of 33% year-over-year in Q3 2025.
• Achieved its eighth consecutive quarter of sequential revenue growth.
• Reported GAAP net income of $0.6 million in Q3 2025, a significant improvement from a net loss in Q3 2024.
• Increased non-GAAP adjusted EBITDA to $7.8 million (28% of revenue) in Q3 2025, demonstrating improved profitability and margin expansion.
• Successfully divested the non-core evo cold chain logistics business for $25.5 million, streamlining focus on the core cell processing business.
• Raised full-year 2025 Cell Processing revenue guidance and total revenue guidance, reflecting confidence in continued growth.
• Maintains a strong market position with over 70% market share in biopreservation media for U.S. commercially sponsored clinical trials.
• Anticipates further growth with 10 additional commercial CGT product approvals or expansions expected within the next 12 months.

Negatives

• GAAP gross margin decreased to 62% in Q3 2025 from 63% in Q3 2024.
• Non-GAAP adjusted gross margin decreased to 64% in Q3 2025 from 67% in Q3 2024.
• The decreases in gross margin were attributed to an inventory reserve of approximately $0.6 million recorded during Q3 2025 and product mix.
• GAAP net loss for the nine months ended September 30, 2025, was $15.7 million, an increase from $9.2 million for the same period in 2024.

Risks

• Forward-looking statements involve a number of risks and uncertainties that are difficult to predict and could cause actual results to differ materially from expectations.
• A description of certain risks, uncertainties, and other matters can be found in filings with the U.S. Securities and Exchange Commission.

Future Outlook

BioLife Solutions has raised its full-year 2025 Cell Processing revenue guidance to $93.0 million $94.0 million and its total revenue guidance (adjusted for the evo sale) to $95.0 million $96.0 million. The company anticipates 10 additional commercial cell and gene therapy product approvals, geographic expansions, earlier lines of treatment, or new indications over the next 12 months. Management expects 2025 GAAP gross margin in the low-60% range and non-GAAP adjusted gross margin in the mid-60% range, along with a reduction in GAAP net loss and continued expansion of non-GAAP adjusted EBITDA margin compared to 2024.

Management Comments

• Roderick de Greef, Chairman and CEO, commented: "We delivered another strong quarter, with cell processing revenue up 33% year over year and our eighth consecutive quarter of sequential growth."
• Roderick de Greef stated: "Performance reflected healthy growth across our biopreservation media (BPM) franchise and our broader cell processing tools portfolio, led by continued momentum from commercial BPM customers."
• Roderick de Greef noted: "By aligning the organization around our core cell processing business, we are driving sustainable, high-quality growth and expanding profitability, achieving another quarter of adjusted EBITDA margin improvement both year over year and sequentially."
• Roderick de Greef highlighted: "The divestiture of our evo cold chain logistics business in early October has reshaped BioLife into a leading pure-play cell processing company centered on our highest-value, recurring revenue franchises. This streamlined profile, solid financial position and market leading product portfolio provide a strong foundation for continued profitable growth and long-term value creation."

Industry Context

BioLife Solutions operates as a key enabler in the rapidly expanding cell and gene therapy (CGT) market, providing essential cell processing tools and services. The strong growth in its core cell processing revenue and its dominant market share in biopreservation media for clinical trials underscore its alignment with the robust demand within the CGT sector. The strategic divestiture of its cold chain logistics business further sharpens its focus on this high-growth, specialized segment, positioning it as a pure-play provider in a critical part of the CGT value chain.

Comparison to Industry Standards

• The filing highlights BioLife Solutions' strong market share in biopreservation media, utilized in over 70% of ongoing commercially sponsored clinical trials in the U.S., including nearly 80% of Phase III trials. This indicates a leading position within its specific niche of the cell and gene therapy market.
• No specific comparable companies, projects, or direct competitive results are detailed in the filing to allow for a direct assessment against global benchmarks.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong financial performance, increased profitability, raised guidance, and a clearer strategic focus on the high-growth core business. The cash proceeds from the evo divestiture also strengthen the balance sheet.
• Customers (Cell and Gene Therapy market): Continued and potentially enhanced support through a focused provider of critical cell processing tools and services, ensuring the health and function of biologic materials.
• Employees: The strategic streamlining of the business towards core cell processing may offer more focused growth opportunities, though the divestiture of evo would have impacted employees associated with that subsidiary.

Next Steps

• Management will discuss the financial results and provide a general business update during a conference call and live webcast on November 6, 2025, at 4:30 p.m. ET.
• Expectations for approvals of 10 additional commercial CGT products, geographic expansions, earlier lines of treatment, or new indications over the next 12 months.
• The divestiture of evo is anticipated to qualify and be presented as Discontinued Operations in the Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

BioLife Solutions delivered robust Q3 2025 results, significantly increasing Cell Processing revenue by 33% year-over-year and achieving GAAP net income after a prior-year loss. The substantial improvement in adjusted EBITDA and its margin, coupled with an upward revision of full-year revenue guidance, demonstrates strong operational momentum and effective strategic execution. The divestiture of the evo cold chain logistics business further streamlines the company's focus on its high-growth, high-margin core cell and gene therapy processing tools and services, where it holds a dominant market share in critical biopreservation media. This strategic clarity, combined with a solid financial position and positive outlook for future commercial therapy approvals, positions BioLife Solutions for continued profitable growth and long-term value creation, making it a compelling investment.

Keywords

BioLife Solutions, BLFS, Cell Processing, Cell and Gene Therapy, Biopreservation Media, Cryogenic Vials, Financial Results, Q3 2025, Revenue Guidance, Divestiture, EBITDA, GAAP, Non-GAAP